EVE Health Group Limited - Asset Resilience Ratio

Latest as of December 2025: 22.86%

EVE Health Group Limited (EVE) has an Asset Resilience Ratio of 22.86% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read EVE total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

AU$929.66K
≈ $657.79K USD Cash + Short-term Investments

Total Assets

AU$4.07 Million
≈ $2.88 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how EVE Health Group Limited's Asset Resilience Ratio has changed over time. See EVE total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down EVE Health Group Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EVE market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$929.66K 22.86%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$929.66K 22.86%

Asset Resilience Insights

  • Good Liquidity Position: EVE Health Group Limited maintains a healthy 22.86% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

EVE Health Group Limited Industry Peers by Asset Resilience Ratio

Compare EVE Health Group Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
B&G Foods Inc
NYSE:BGS
Packaged Foods 2.07%
Orkla ASA
OL:ORK
Packaged Foods 4.19%
New Hope Dairy Co Ltd
SHE:002946
Packaged Foods 2.26%
Zhe Jiang Li Zi Yuan Food Co Ltd
SHG:605337
Packaged Foods 6.20%
DXN HOLDINGS BHD.
KLSE:5318
Packaged Foods 0.45%
Tangrenshen Group Co Ltd
SHE:002567
Packaged Foods 0.08%
Haoxiangni Jujube Co Ltd
SHE:002582
Packaged Foods 6.50%
Beingmate Baby & Child Food Co Ltd
SHE:002570
Packaged Foods 0.02%

Annual Asset Resilience Ratio for EVE Health Group Limited (2011–2025)

The table below shows the annual Asset Resilience Ratio data for EVE Health Group Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 21.90% AU$903.42K
≈ $639.23K
AU$4.12 Million
≈ $2.92 Million
+17.69pp
2024-06-30 4.21% AU$106.17K
≈ $75.12K
AU$2.52 Million
≈ $1.79 Million
-9.45pp
2022-06-30 13.66% AU$1.10 Million
≈ $780.03K
AU$8.07 Million
≈ $5.71 Million
-12.85pp
2021-06-30 26.50% AU$3.16 Million
≈ $2.24 Million
AU$11.92 Million
≈ $8.44 Million
-9.90pp
2020-06-30 36.41% AU$5.14 Million
≈ $3.64 Million
AU$14.11 Million
≈ $9.99 Million
+31.24pp
2019-06-30 5.17% AU$453.78K
≈ $321.08K
AU$8.78 Million
≈ $6.21 Million
-49.98pp
2018-06-30 55.15% AU$4.11 Million
≈ $2.91 Million
AU$7.46 Million
≈ $5.28 Million
+42.33pp
2017-06-30 12.82% AU$393.62K
≈ $278.51K
AU$3.07 Million
≈ $2.17 Million
+1.66pp
2015-06-30 11.16% AU$309.52K
≈ $219.01K
AU$2.77 Million
≈ $1.96 Million
+7.00pp
2014-06-30 4.16% AU$340.95K
≈ $241.25K
AU$8.19 Million
≈ $5.79 Million
+0.22pp
2013-06-30 3.94% AU$325.50K
≈ $230.31K
AU$8.26 Million
≈ $5.84 Million
+0.47pp
2012-06-30 3.48% AU$823.02K
≈ $582.34K
AU$23.68 Million
≈ $16.76 Million
-21.68pp
2011-06-30 25.16% AU$6.71 Million
≈ $4.75 Million
AU$26.68 Million
≈ $18.88 Million
--
pp = percentage points

About EVE Health Group Limited

AU:EVE Australia Packaged Foods
Market Cap
$6.68 Million
AU$9.44 Million AUD
Market Cap Rank
#27770 Global
#1471 in Australia
Share Price
AU$0.03
Change (1 day)
-3.57%
52-Week Range
AU$0.00 - AU$0.04
All Time High
AU$0.04
About

EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erect… Read more